Strategic Focus
The center aims to carry out research in the areas of cell and molecular biology. A major thrust area will be Stem Cell Research and Clinical Applications. Another focus of the center will be Molecular Diagnostics.
Cell & Molecular Biology Research Center (CMBRC):
Constructed in 4000 sq ft of space, with 2000 sq ft converted to a Class 10,000 cell culture facility. Along with this the center also has a Committee Room cum Library and 2 large labs for Cell and Molecular biology research.
The center aims to undertake the following activities-
- Stem cell research
- Training Programs
- Clinical Trials involving Stem Cells followed by therapy in promising areas
- Supplying stem cells to outside institutes for clinical trials /therapy
- Diagnostics – Basic and applied
Our Team
Dr. Ashok Khar, Director
Dr. Preeti Kapoor, Senior Scientist and Group Leader
Research Assistants
Potential for Collaboration
- Open to collaborations with top institutions in the country and outside India.
- Submission of joint project proposals for financial support from Government agencies is another agenda.
Projects in the pipeline:
A randomized controlled trial using autologous bone marrow derived mesenchymal stem cells for the treatment of cerebral palsy
Principal Investigator: Prof. Veena Kalra
Senior Consultant, Paediatric Neurology
Indraprastha Apollo Hospitals, New Delhi
Project duration: 2 years
Co-investigator:
Dr. Koninika Ray
Scientific Consultant, AHERF, New Delhi
| Facts on Cerebral Palsy: |
- Nonprogressive neuromotor disorder
- Caused by lesions or anomalies in the developing brain
- During prenatal, perinatal and postnatal periods |
| Typical Symptoms: |
Abnormality of motor/tone, seizures, hearing loss,
difficulty in speaking, blindness, lack of co-ordination and/or
mental retardation |
| Broadly divided into: |
Spastic, Ataxic, Athetoid/diskinetic and Mixed |
| Incidence: |
2-2.5/1000 live births |
Objective
- To carry out a randomized controlled trial using autologous bone marrow derived mesenchymal stem cells for therapy in 60 children diagnosed with cerebral palsy
- To study the effect of Granulocyte – Colony Stimulating Factor administered concurrent with autologous mesenchymal stem cell transfusion on outcome parameters in children with cerebral palsy
|